CYPHERPUNK TECHNOLOGIES INC. Operating Expenses
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Operating Expenses of $4.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for the quarter ending 2026-06-30 was $4.69M, a 72.22% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for the quarter ending 2026-03-31 was $4.82M, a 69.74% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for the quarter ending 2025-12-31 was $5.10M, a 68.35% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for the quarter ending 2025-09-30 was $3.17M, a 82.27% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for fiscal 2025 was $41.07M, a 41.38% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for fiscal 2024 was $70.06M, a 19.51% decline from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for fiscal 2023 was $87.04M, a 53.34% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. operating expenses for fiscal 2022 was $56.76M, a 32.23% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.69M 10-Q · filed 2026-08-12 | $9.51M 10-Q · filed 2026-08-12 | $14.61M derived: sum of 3 quarters · filed 2026-08-12 | $17.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $4.82M 10-Q · filed 2026-05-14 | $9.92M derived: sum of 2 quarters · filed 2026-05-14 | $13.09M derived: sum of 3 quarters · filed 2026-05-14 | $29.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.27M derived: sum of 2 quarters · filed 2026-03-16 | $25.15M derived: sum of 3 quarters · filed 2026-08-12 | $41.07M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.17M 10-Q · filed 2025-11-12 | $20.05M derived: sum of 2 quarters · filed 2026-08-12 | $35.96M 10-Q · filed 2025-11-12 | $52.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $16.88M 10-Q · filed 2026-08-12 | $32.80M 10-Q · filed 2026-08-12 | $48.92M derived: sum of 3 quarters · filed 2026-08-12 | $66.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $15.92M 10-Q · filed 2026-05-14 | $32.04M derived: sum of 2 quarters · filed 2026-05-14 | $49.90M derived: sum of 3 quarters · filed 2026-05-14 | $71.15M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $16.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $33.98M derived: sum of 2 quarters · filed 2026-03-16 | $55.23M derived: sum of 3 quarters · filed 2026-03-16 | $70.06M 10-K · filed 2026-03-16 |
| 2024-09-30 | $17.86M 10-Q · filed 2025-11-12 | $39.11M derived: sum of 2 quarters · filed 2025-11-12 | $53.93M 10-Q · filed 2025-11-12 | $68.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $21.25M 10-Q · filed 2025-08-14 | $36.08M 10-Q · filed 2025-08-14 | $50.90M derived: sum of 3 quarters · filed 2025-08-14 | $65.73M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $14.82M 10-Q · filed 2025-05-13 | $29.64M derived: sum of 2 quarters · filed 2025-05-13 | $44.48M derived: sum of 3 quarters · filed 2025-05-13 | $59.14M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $14.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $29.65M derived: sum of 2 quarters · filed 2025-03-26 | $44.31M derived: sum of 3 quarters · filed 2025-03-26 | $87.04M 10-K · filed 2025-03-26 |
| 2023-09-30 | $14.83M 10-Q · filed 2024-11-13 | $29.50M derived: sum of 2 quarters · filed 2024-11-13 | $72.22M 10-Q · filed 2024-11-13 | $86.16M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $14.66M 10-Q · filed 2024-08-12 | $57.39M 10-Q · filed 2024-08-12 | $71.33M derived: sum of 3 quarters · filed 2024-08-12 | $86.62M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $42.73M 10-Q · filed 2024-05-13 | $56.67M derived: sum of 2 quarters · filed 2024-05-13 | $71.96M derived: sum of 3 quarters · filed 2024-05-13 | $88.86M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $29.23M derived: sum of 2 quarters · filed 2024-03-18 | $46.13M derived: sum of 3 quarters · filed 2024-03-18 | $56.76M 10-K · filed 2024-03-18 |
| 2022-09-30 | $15.29M 10-Q · filed 2023-11-13 | $32.19M derived: sum of 2 quarters · filed 2023-11-13 | $42.82M 10-Q · filed 2023-11-13 | $53.68M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $16.90M 10-Q · filed 2023-08-14 | $27.53M 10-Q · filed 2023-08-14 | $38.40M derived: sum of 3 quarters · filed 2023-08-14 | $50.91M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.63M 10-Q · filed 2023-05-15 | $21.50M derived: sum of 2 quarters · filed 2023-05-15 | $34.01M derived: sum of 3 quarters · filed 2023-05-15 | $44.01M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $23.38M derived: sum of 2 quarters · filed 2023-03-24 | $33.38M derived: sum of 3 quarters · filed 2023-03-24 | $42.93M 10-K · filed 2023-03-24 |
| 2021-09-30 | $12.52M 10-Q · filed 2022-11-14 | $22.52M derived: sum of 2 quarters · filed 2022-11-14 | $32.06M 10-Q · filed 2022-11-14 | $39.59M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.00M 10-Q · filed 2022-08-12 | $19.55M 10-Q · filed 2022-08-12 | $27.08M derived: sum of 3 quarters · filed 2022-08-12 | $34.96M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $9.55M 10-Q · filed 2022-05-13 | $17.08M derived: sum of 2 quarters · filed 2022-05-13 | $24.96M derived: sum of 3 quarters · filed 2022-05-13 | $32.83M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $7.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $15.41M derived: sum of 2 quarters · filed 2022-03-11 | $23.28M derived: sum of 3 quarters · filed 2022-03-11 | $30.04M 10-K · filed 2022-03-11 |
| 2020-09-30 | $7.88M 10-Q · filed 2021-11-12 | $15.75M derived: sum of 2 quarters · filed 2021-11-12 | $22.51M 10-Q · filed 2021-11-12 | $30.78M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $7.87M 10-Q · filed 2021-08-13 | $14.63M 10-Q · filed 2021-08-13 | $22.90M derived: sum of 3 quarters · filed 2021-08-13 | $30.82M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $6.76M 10-Q · filed 2021-05-14 | $15.03M derived: sum of 2 quarters · filed 2021-05-14 | $22.95M derived: sum of 3 quarters · filed 2021-05-14 | $31.41M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $16.20M derived: sum of 2 quarters · filed 2021-03-12 | $24.66M derived: sum of 3 quarters · filed 2021-03-12 | $33.45M 10-K · filed 2021-03-12 |
| 2019-09-30 | $7.92M 10-Q · filed 2020-11-12 | $16.38M derived: sum of 2 quarters · filed 2020-11-12 | $25.18M 10-Q · filed 2020-11-12 | $34.15M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $8.46M 10-Q · filed 2020-08-13 | $17.26M 10-Q · filed 2020-08-13 | $26.23M derived: sum of 3 quarters · filed 2020-08-13 | $34.83M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $8.79M 10-Q · filed 2020-05-14 | $17.77M derived: sum of 2 quarters · filed 2020-05-14 | $26.36M derived: sum of 3 quarters · filed 2020-05-14 | $33.20M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $17.57M derived: sum of 2 quarters · filed 2020-03-16 | $24.41M derived: sum of 3 quarters · filed 2020-03-16 | $30.75M 10-K · filed 2020-03-16 |
| 2018-09-30 | $8.60M 10-Q · filed 2019-11-14 | $15.44M derived: sum of 2 quarters · filed 2019-11-14 | $21.78M 10-Q · filed 2019-11-14 | $28.33M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $6.84M 10-Q · filed 2019-08-09 | $13.18M 10-Q · filed 2019-08-09 | $19.73M derived: sum of 3 quarters · filed 2019-08-09 | $28.31M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $6.34M 10-Q · filed 2019-05-15 | $12.89M derived: sum of 2 quarters · filed 2019-05-15 | $21.47M derived: sum of 3 quarters · filed 2019-05-15 | $28.49M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $15.13M derived: sum of 2 quarters · filed 2019-04-01 | $22.14M derived: sum of 3 quarters · filed 2019-04-01 | $32.35M 10-K · filed 2019-04-01 |
| 2017-09-30 | $8.58M 10-Q · filed 2018-11-09 | $15.60M derived: sum of 2 quarters · filed 2018-11-09 | $25.81M 10-Q · filed 2018-11-09 | $33.74M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $7.02M 10-Q · filed 2018-08-08 | $17.22M 10-Q · filed 2018-08-08 | $25.16M derived: sum of 3 quarters · filed 2018-08-08 | $32.19M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $10.21M 10-Q/A · filed 2018-08-08 | $18.15M derived: sum of 2 quarters · filed 2018-08-08 | $25.18M derived: sum of 3 quarters · filed 2018-08-08 | $32.37M derived: sum of 4 quarters · filed 2018-08-08 |
| 2016-12-31 | $7.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $14.97M derived: sum of 2 quarters · filed 2018-02-23 | $22.16M derived: sum of 3 quarters · filed 2018-02-23 | $27.30M 10-K · filed 2018-02-23 |
| 2016-09-30 | $7.03M 10-Q · filed 2017-11-13 | $14.22M derived: sum of 2 quarters · filed 2017-11-13 | $19.36M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | $7.19M 10-Q · filed 2017-08-11 | $12.34M 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $5.14M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |